Advertisement
Product › Details
Onfi™
Next higher product group | clobazam | |
Status | 2012-01-03 sales start | |
Organisation | H. Lundbeck A/S | |
Group | Lundbeck (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for CNS drug (neurological drug)
- [1] FundaMental Pharma GmbH. (4/11/24). "Press Release: FundaMental Pharma Appoints Dr. Dirk Beher as Chief Executive Officer". Heidelberg....
- [2] Merz Asset Management Holding GmbH & Co. KG. (4/2/24). "Press Release: Merz Enters Asset Purchase Agreement with a US-based Biotech Company". Frankfurt am Main....
- [3] Engrail Therapeutics, Inc.. (3/19/24). "Press Release: Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies". San Diego, CA....
- [4] Sosei Group Corporation (d/b/a Sosei Heptares). (3/11/24). "Press Release: Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-in-class Treatments Targeting All Symptoms of Schizophrenia". Ingelheim, Tokyo & Cambridge....
- [5] Bristol Myers Squibb Company. (12/22/23). "Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics". Princeton, N.J. & Boston, MA....
- [6] Vandria S.A.. (12/14/23). "Press Release: Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform". Lausanne....
- [7] Merck & Co., Inc.. (11/21/23). "Press Release: Merck to Acquire Caraway Therapeutics, Inc.". Rahway, NJ & Cambridge, MA....
- [8] Autifony Therapeutics Ltd.. (11/14/23). "Press Release: Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders". Stevenage....
- [9] VectorY Therapeutics B.V.. (11/13/23). "Press Release: VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases". Amsterdam....
- [10] Kynexis B.V.. (11/7/23). "Press Release: Kynexis Launched to Advance Precision Therapeutics for Brain Diseases". Naarden....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top